Myotonic dystrophies - Phenotypes, pothogenesis, diognostics and therapy: Proceedings of a symposium at the German Neurowoche 2006, Mannheim, Germany;Myotone dystrophien - Phänotypen, pathogenese, diagnostik und therapie zusammenfassung eines minisymposiums im Rahmen der Neurowoche 2006, Mannheim

Nervenheilkunde

Volumn 26, Issue 1-2, 2007, Pages 74-78

  Schoser, Benedikt G H ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

DM1; DM2; Myotonic dystrophy; Repeat disorder; Treatment

Indexed keywords

CHROMOSOME 19Q; CHROMOSOME 3Q; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; GENE MUTATION; GERMANY; HUMAN; MYOTONIC DYSTROPHY; NEUROPATHOLOGY; PATHOGENESIS; PHENOTYPE; RICKER DISEASE; RNA SPLICING;

EID: 33847768560     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626835     Document Type: Conference Paper

References (38)

1. Bachinski LL et al. Confirmation of DM2 (CCTG)n expansion mutation in PROMM/PDM patients of different European origins: a single shared haplotype indicates ancestral founder effects. Am J Hum Genet 2003; 73: 835-48.
2. Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J. 2004; 147: 224-47.
3. Brook JD et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992; 68: 799-808.
4. Cho DH, Tapscott SJ. Myotonic dystrophy: Emerging mechanisms for DM1 and DM2. Biochim Biophys Acta 2006; PMID: 16876389
5. Gaul C et al. Subtle cognitive dysfunction in adult myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 2006; 67: 350-2.
6. George A et al. Musculoskeletal pain as the most prominent feature in myotonic dystrophy type 2 Schmerz. 2006 PMID: 16758212.
7. George A et al. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol 2004; 61: 1938-42.
8. Gomes-Pereira M, Monckton DG. Chemical modifiers of unstable expanded simple sequence repeats: what goes up, could come down. Mutat Res 2006; 598: 15-34.
9. rd edition. London: W. B. Sauders 2001.
10. Jakubiczka S et al. A strategy for reliable diagnosis of PROMM/DM2. Neurogenetics 2004; 5: 55-9.
11. Kanadia RN et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci USA. 2006; 103: 11748-53.
12. Kassubek J et al. Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging study. Neurosci Lett 2003; 348: 73-6.
13. Kornblum C et al. Distinct neuromuscular phenotypes in myotonic dystrophy types 1 and 2: a whole body highfield MRI study. J Neurol 2006; 253: 753-61.
14. Kornblum C et al. Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2. J Neurol 2004; 251: 710-4.
15. Langlois MA et al. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem 2005; 280: 16949-54.
16. Leroy O et al. ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. J Neurosci Res 2006; 84: 852-9.
17. Liquori CL et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293: 864-7.
18. Liquori CL et al. Myotonic Dystrophy Type 2: Human founder haplotype and evolutionary conservation of the repeat tract. Am J Hum Genet 2003; 73: 849-62.
19. Mahadevan M et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 1992; 255: 1253-5.
20. Mahadevan MS et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006; 38: 1066-70.
21. Margolis JM et al. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 2006; 15: 1808-15.
22. Maurage CA et al. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology 2005; 65: 1636-8.
23. Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol Genet 2006; 15: 162-9.
24. Ota M et al. Relationship between diffusion tensor imaging and brain morphology in patients with myotonic dystrophy. Neurosci Lett 2006; 407: 234-9.
25. Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci 2006; 29: 259-77.
26. Rudnik-Schoneborn S et al. Outcome and effect of pregnancy in myotonic dystrophy type 2. Neurology 2006; 66: 579-80.
27. Ricker K et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44: 1448-52
28. Schara U, Schoser BG. Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin Pediatr Neurol 2006; 13: 71-9.
29. Schneider-Gold C et al. Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): a quantitative 31P-MRS and MRI study. Muscle Nerve 2004; 30: 636-44.
30. Schoser BG. Myotone Dystrophien - Aktueller Stand der molekularen Pathogenese. Akt Neurol 2005; 32: 324-30.
31. Schoser BG et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004; 63: 2402-4.
32. Sergeant N et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 2001; 10: 2143-55.
33. rd edition. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994; 35: 269-72.
34. Timchenko NA et al. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001; 276: 7820-6.
35. Timchenko L. Reversal of fortune. Nat Genet 2006; 38: 976-7.
36. rd Workshop, 14-16 February 2003, Naarden, The Netherlands. Neuromuscl Disord 2003; 13: 589-96.
37. th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006; 16: 403-13.
38. Vielhaber S et al. Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1. Muscle Nerve 2006; 34: 145-52.